Analyst Ratings January 29, 2026

Lucid Capital Markets Starts Coverage on Adlai Nortye, Assigns Buy and $11 Target

Analyst flags AN9025 pan-RAS inhibitor as primary value driver while noting near-term financing needs

By Caleb Monroe ANL
Lucid Capital Markets Starts Coverage on Adlai Nortye, Assigns Buy and $11 Target
ANL

Lucid Capital Markets has opened coverage on Adlai Nortye Ltd. (NASDAQ: ANL) with a Buy rating and an $11 price objective, implying roughly 217% upside from the stock's current $3.47 level. The firm highlights the company's pan-RAS inhibitor, AN9025, as the main potential catalyst and models peak non-risk adjusted revenues of about $3.2 billion for the program. Lucid also flags cash constraints following a first-half 2025 cash balance of about $44.1 million and recent operating losses.

Key Points

  • Lucid Capital Markets initiated coverage of Adlai Nortye (NASDAQ: ANL) with a Buy rating and a price target of $11.00, implying about 217% upside from $3.47.
  • The pan-RAS inhibitor AN9025 is the primary value driver in Lucid's thesis, contributing roughly $9 per share of the $11 target; Lucid models peak non-risk adjusted revenues near $3.2 billion for the program.
  • Corporate and market impacts include biotech and pharmaceutical sectors due to potential oncology market opportunity and regional commercialization through a $230 million licensing deal with ASK Pharm covering mainland China, Hong Kong, and Macao.

Lucid Capital Markets has initiated coverage of Adlai Nortye Ltd. (NASDAQ: ANL) with a Buy recommendation and a price target of $11.00, which the firm says represents roughly a 217% upside from the stock's current trading price of $3.47. The initiation comes as the clinical-stage biotechnology company has posted strong market momentum, evidenced by a 144% year-to-date gain cited from InvestingPro data.

At the center of Lucid's valuation is AN9025, Adlai Nortye's investigational pan-RAS inhibitor. The analyst team views this asset as the principal value driver for the company if clinical development progresses and the program is de-risked. In modeling the company's upside, Lucid allocates about $9 of the $11 target to AN9025, with the remaining approximately $2 per share ascribed to the broader pipeline and platform.

Lucid characterizes AN9025's preclinical profile as compelling when compared to selected competitors, but it stresses that confirmatory data from human clinical trials will be required to validate any therapeutic advantages. The pan-RAS approach targets cancers driven by RAS mutations, which Lucid notes account for more than 30% of all cancers, underscoring the potential scale if the program proves successful.

In its forecast, Lucid projects the AN9025 opportunity could translate into roughly $3.2 billion in peak non-risk adjusted revenues. The firm expects that meaningful de-risking could occur as potential clinical data readouts approach in 2026, a timeline Lucid uses to justify part of its upside case.

While the valuation work emphasizes the promise of AN9025, the firm also highlights balance-sheet realities. Adlai Nortye finished the first half of 2025 with about $44.1 million in cash and equivalents, and Lucid notes the company may require additional financing in the near term. Supporting that liquidity concern, InvestingPro data cited in the coverage indicates the company is "quickly burning through cash," listing an EBITDA of -$41.88 million and a debt-to-equity ratio of 5.63.

Separately, Adlai Nortye recently agreed to a licensing transaction with ASK Pharm valued at $230 million. The arrangement grants ASK Pharm exclusive rights to develop, manufacture, and commercialize AN9025 within mainland China, Hong Kong, and Macao, while Adlai Nortye retains rights to the asset outside those territories. Lucid frames the deal as a strategic step to advance AN9025's development and commercialization in Greater China through a regional partner focused on those markets, while Adlai Nortye concentrates on the rest of the world.

Overall, Lucid's initiation ties a substantial portion of its Buy thesis to the future clinical performance and commercialization prospects of AN9025, while also drawing attention to near-term funding needs and current negative operating results. Investors seeking additional financial metrics and analysis were directed to resources that provide further company data and proprietary 'ProTips.' The coverage presents a clear upside case driven by a single lead asset alongside tangible financial and execution risks.


Note: The article reports analyst views and company-reported financial figures without endorsement or recommendation beyond the coverage described.

Risks

  • Clinical risk - AN9025's potential depends on future human trial results; Lucid notes preclinical promise but stresses that clinical confirmation is required. This impacts the biotech and pharmaceutical sectors.
  • Financing and cash burn - Adlai Nortye ended H1 2025 with about $44.1 million in cash and is running significant losses (EBITDA -$41.88 million), suggesting it may need additional financing soon. This affects investors and capital markets exposure to small-cap biotech.
  • Execution and partnership concentration - While the ASK Pharm licensing deal covers Greater China, Adlai Nortye retains rights elsewhere. The commercial and development execution across regions could influence the asset's global value and partnership dynamics in the pharmaceutical sector.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026